Background: Previous studies suggest that mpox vaccination reduces disease severity among breakthrough infections, but these studies relied on unadjusted comparisons without accounting for confounding by age or health status. We compared disease severity between vaccinated and unvaccinated mpox cases after adjusting for potential confounders. We also evaluated whether time since vaccination was associated with mpox disease severity.Methods: We conducted a retrospective analysis of all confirmed and probable mpox cases reported in Washington State from January 1, 2023 to June 30, 2025, using state surveillance data supplemented by medical record abstraction. Disease severity was measured using an adapted Mpox Severity Scoring System. Individuals were classified as vaccinated if they received at least one dose of the MVA-BN vaccine at least 14 days before symptom onset. Linear regression was used to estimate the associations between vaccination status and disease severity, adjusting for age and immunocompromising conditions. Among vaccinated individuals, we used linear regression to examine associations between time since last vaccine dose (<12 months, 12-<24 months, 24+ months) and disease severity.Findings: Of the 175 reported mpox cases, 164 cases met inclusion criteria; 94 (57%) were vaccinated and 70 (43%) were unvaccinated. The mean mpox severity score among vaccinated individuals was 4·6 (95% CI 4·3-4·9). Vaccination was associated with a 1·44-point lower severity score (0·79-2·09, p<0·001), and with a 1·48-point lower score after adjusting (0·77-2·19, p24 months prior to infection had a 0·97-point higher severity score than those vaccinated within the previous year (0·07-1·87, p=0·035). After adjusting, the difference was 0·93 points (-0·12-1·98, p=0·082).Interpretation: Mpox vaccination was associated with lower disease severity after adjustment for measured confounders. Individuals vaccinated more than two years before infection may be at risk of more severe disease than those vaccinated more recently.